NAMSW NewAmsterdam Pharma Company N.V
$12.52▲ +0.00%
Healthcare
Other
Volume 48
Avg Volume (10D) 850
Key Metrics & Fundamentals
Market Cap
–
P/E Ratio
–
Div Yield
–%
52W Range
11.10 - 30.45
% vs 50 MA
-34.94%
% vs 200 MA
-45.07%
RSI-14
16.0
MACD Histogram
-0.3900
Beta (1Y vs SPY)
0.60
Free Cash Flow
-$39.29M
Gross Rev
$3.70M
Gross Profit
$3.70M
EBITDA
-$59.72M
COGS
–
Operating Exp
$68.57M
Operating Income
-$64.86M
EBIT
-$64.86M
Pretax Income
-$64.14M
Net Income
-$64.14M
Price & Volume History
Loading chart…
Recent News
How Novartis' Double-Stacked Failures Reverberated Through Biopharma
Investor's Business Daily · Sep 8, 2026 8:26 PM
Novartis Trial Failure Sparks Biopharma Options Frenzy
Schaeffer's Investment Research · Sep 8, 2026 4:07 PM
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 3, 2026 8:01 PM
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
GlobeNewswire · Sep 2, 2026 12:00 PM
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
GlobeNewswire · Aug 26, 2026 12:00 PM
RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating
MT Newswires · Aug 6, 2026 12:53 PM
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
MarketBeat · Aug 5, 2026 5:04 PM
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
Zacks · Aug 5, 2026 1:55 PM
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
GlobeNewswire · Aug 5, 2026 11:00 AM
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
GlobeNewswire · Jul 29, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See NAMSW's money flow as a full page
Social Sentiment
No Reddit posts found for NAMSW.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.